Skip to content

Study · Observational study · 2017

8 results

Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.

Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD, Botros FT

Diabetes, obesity & metabolism24 Nov 2016Cited by 54 (Europe PMC)

PMID27766728 (opens in a new tab)PMCIDPMC5347883 (opens in a new tab)DOI10.1111/dom.12816 (opens in a new tab)PepBankPUB-27766728
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In pooled trials in people with T2D, eGFR did not differ significantly between dulaglutide and placebo.

    In plain wordsIn pooled trials in people with T2D, kidney filtration did not differ significantly between dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeeGFR versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR (mean)
    87.8 mL/min/1.73 m²
    dulaglutide
    eGFR (mean)
    88.2 mL/min/1.73 m²
    placebo

    Source sentences

    Summary
    No significant differences in eGFR were observed during treatment for dulaglutide vs placebo, active comparators or insulin glargine
    2 context sentences
    Summary · context
    dulaglutide vs placebo: 87.8 ± 17.7 vs 88.2 ± 17.9 mL/min/1.73 m2 , P = .075
    Summary · context
    Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs).
  2. 02HumanObservational studyEfficacy outcome

    In pooled trials in people with T2D, eGFR did not differ significantly between dulaglutide and active comparators.

    In plain wordsIn pooled trials in people with T2D, kidney filtration did not differ significantly between dulaglutide and active comparators.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeeGFR versus active comparators
    Study

    n: not reported in source

    Comparator
    Active comparators
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR (mean)
    89.9 mL/min/1.73 m²
    dulaglutide
    eGFR (mean)
    88.8 mL/min/1.73 m²
    active comparators

    Source sentences

    Summary
    No significant differences in eGFR were observed during treatment for dulaglutide vs placebo, active comparators or insulin glargine
    2 context sentences
    Summary · context
    dulaglutide vs active comparators: 89.9 ± 16.7 vs 88.8 ± 16.3 mL/min/1.73 m2 , P = .223
    Summary · context
    Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs).
  3. 03HumanObservational studyEfficacy outcome

    In pooled trials in people with T2D, eGFR did not differ significantly between dulaglutide and insulin glargine.

    In plain wordsIn pooled trials in people with T2D, kidney filtration did not differ significantly between dulaglutide and insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeeGFR versus insulin glargine
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR (mean)
    85.9 mL/min/1.73 m²
    dulaglutide
    eGFR (mean)
    83.9 mL/min/1.73 m²
    insulin glargine

    Source sentences

    Summary
    No significant differences in eGFR were observed during treatment for dulaglutide vs placebo, active comparators or insulin glargine
    2 context sentences
    Summary · context
    and dulaglutide vs insulin glargine: 85.9 ± 18.2 vs 83.9 ± 18.6 mL/min/1.73 m2 , P = .423).
    Summary · context
    Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs).
  4. 04HumanObservational studyEfficacy outcome

    In pooled trials in people with T2D, UACR was lower with dulaglutide than placebo.

    In plain wordsIn pooled trials in people with T2D, urinary albumin relative to creatinine was lower with dulaglutide than placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseUACR versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    UACR median
    8 mg/g
    dulaglutide, week 26
    UACR Q1-Q3
    4.4 to 20.4 mg/g
    dulaglutide, week 26
    UACR median
    8 mg/g
    placebo, week 26
    UACR Q1-Q3
    4.4 to 23.9 mg/g
    placebo, week 26

    Source sentences

    Summary
    Lower UACR values were observed for dulaglutide vs placebo, active comparators and insulin glargine
    2 context sentences
    Summary · context
    dulaglutide vs placebo: 8.0 [4.4-20.4] vs 8.0 [4.4-23.9] mg/g, P = .023
    Summary · context
    Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs).
  5. 05HumanObservational studyEfficacy outcome

    In pooled trials in people with T2D, UACR was lower with dulaglutide than active comparators.

    In plain wordsIn pooled trials in people with T2D, urinary albumin relative to creatinine was lower with dulaglutide than active comparators.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseUACR versus active comparators
    Study

    n: not reported in source

    Comparator
    Active comparators
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    UACR median
    8 mg/g
    dulaglutide, week 26
    UACR Q1-Q3
    4.4 to 21.2 mg/g
    dulaglutide, week 26
    UACR median
    8.9 mg/g
    active comparators, week 26
    UACR Q1-Q3
    4.4 to 27.4 mg/g
    active comparators, week 26

    Source sentences

    Summary
    Lower UACR values were observed for dulaglutide vs placebo, active comparators and insulin glargine
    2 context sentences
    Summary · context
    dulaglutide vs active comparators: 8.0 [4.4-21.2] vs 8.9 [4.4-27.4] mg/g, P = .013
    Summary · context
    Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs).
  6. 06HumanObservational studyEfficacy outcome

    In pooled trials in people with T2D, UACR was lower with dulaglutide than insulin glargine.

    In plain wordsIn pooled trials in people with T2D, urinary albumin relative to creatinine was lower with dulaglutide than insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseUACR versus insulin glargine
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    UACR median
    8.9 mg/g
    dulaglutide, week 26
    UACR Q1-Q3
    4.4 to 29.2 mg/g
    dulaglutide, week 26
    UACR median
    12.4 mg/g
    insulin glargine, week 26
    UACR Q1-Q3
    5.3 to 50.5 mg/g
    insulin glargine, week 26

    Source sentences

    Summary
    Lower UACR values were observed for dulaglutide vs placebo, active comparators and insulin glargine
    2 context sentences
    Summary · context
    and dulaglutide vs insulin glargine: 8.9 [4.4-29.2] vs 12.4 [5.3-50.5] mg/g, P = .029).
    Summary · context
    Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs).
  7. 07HumanObservational studySafety outcome

    In pooled T2D trials, potential acute renal failure events were numerically more frequent with dulaglutide than active comparators.

    In plain wordsIn pooled T2D trials, potential acute kidney failure events were numerically more frequent with dulaglutide than active comparators.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreasePotential acute renal failure versus active comparators
    Study

    n: not reported in source

    Comparator
    Active comparators
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Potential acute renal failure
    3.4 events/1000 patient-years
    dulaglutide
    Potential acute renal failure
    1.7 events/1000 patient-years
    active comparators

    Source sentences

    Summary
    AEs reflecting potential acute renal failure were 3.4, 1.7 and 7.0 events/1000 patient-years for dulaglutide, active comparators and placebo, respectively.
    1 context sentence
    Summary · context
    Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs).
  8. 08HumanObservational studySafety outcome

    In pooled T2D trials, potential acute renal failure events were numerically less frequent with dulaglutide than placebo.

    In plain wordsIn pooled T2D trials, potential acute kidney failure events were numerically less frequent with dulaglutide than placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasePotential acute renal failure versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Potential acute renal failure
    3.4 events/1000 patient-years
    dulaglutide
    Potential acute renal failure
    7 events/1000 patient-years
    placebo

    Source sentences

    Summary
    AEs reflecting potential acute renal failure were 3.4, 1.7 and 7.0 events/1000 patient-years for dulaglutide, active comparators and placebo, respectively.
    1 context sentence
    Summary · context
    Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.